NANCY KEMENY, M.D.; JOHN DALY, M.D.; BONNIE REICHMAN, M.D.; NANCY GELLER, Ph.D.; JOSÉ BOTET, M.D.; PAULA ODERMAN, R.N.
KEMENY N, DALY J, REICHMAN B, GELLER N, BOTET J, ODERMAN P. Intrahepatic or Systemic Infusion of Fluorodeoxyuridine in Patients with Liver Metastases from Colorectal Carcinoma: A Randomized Trial. Ann Intern Med. 1987;107:459-465. doi: 10.7326/0003-4819-107-4-459
Download citation file:
Published: Ann Intern Med. 1987;107(4):459-465.
Objective: To compare the efficacy of direct hepatic arterial chemotherapy with systemic chemotherapy in patients with liver metastases from colorectal carcinoma.
Design: Randomized trial with crossover allowed from systemic to intrahepatic therapy if tumor progression occurred on systemic therapy.
Setting: Academic medical center, referral-based clinic.
Patients: One hundred sixty-two patients with hepatic metastases from colorectal carcinoma agreed to be randomly assigned to treatment groups. At laparotomy, 63 were excluded from the study: 25 had hepatic resection; 33, extrahepatic disease; 1, infection; and 4, no tumor.
Intervention: Fourteen-day continuous infusion of fluorodeoxyuridine each month using an Infusaid pump (0.3 and 0.15 mg/kg body weight d in the intrahepatic and systemic arms, respectively).
Main Results: Intrahepatic therapy produced a significantly higher complete and partial response rate, 50%, compared with 20% for systemic therapy (p = 0. 001). After tumor progression, 60% of the systemic patients crossed over to intrahepatic therapy; 25% then had a partial response, and 33% a minor response or stabilization of disease on intrahepatic therapy.
Toxicity included ulcer disease (17%) and biliary sclerosis (8%) in patients receiving intrahepatic therapy and diarrhea (70%) in patients receiving systemic therapy. Extrahepatic disease occurred in 56% and 37% of the patients in the intrahepatic and systemic groups, respectively (p = 0.092). The median survivals were 17 and 12 months, for the intrahepatic and systemic groups, respectively.
Conclusion: When compared with systemic therapy, hepatic arterial chemotherapy significantly increases response rate for hepatic metastases from colorectal carcinoma and appears to be a more effective treatment.
Learn more about subscription options.
Register Now for a free account.
Colorectal Cancer, Gastroenterology/Hepatology, Gastrointestinal Cancer, Hematology/Oncology, Liver Cancer.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only